Pramlintide

Pramlintide replaces the activity of amylin, the hormone normally released with insulin after meals. Three amino-acid substitutions help prevent the clumping that makes native human amylin difficult to formulate. AstraZeneca markets the medicine as Symlin/SymlinPen for premeal subcutaneous use.

It slows gastric emptying, suppresses postmeal glucagon and promotes central fullness/reduced food intake. Insulin primarily handles glucose entry into cells, while amylin influences the timing of glucose appearance. Their complementary roles explain add-on use rather than replacement of insulin.

Clinical effects typically include small HbA1c reductions and modest weight loss. Those changes do not make it an interchangeable GLP-1 drug or standalone diabetes treatment.

FDA approved Symlin in 2005. It is used with mealtime insulin in adults with type 1 or type 2diabetes whose glucose goals remain unmet despite insulin treatment, particularly persistent postmeal elevations. Hypoglycemia unawareness and gastroparesis are contraindications.

Common effects include nausea, vomiting, reduced appetite, headache and hypoglycemia. The boxed warning concerns severe insulin-induced low glucose, usually within three hours after injection when pramlintide is added to insulin.

Insulin doses are reduced during initiation according to the prescribing plan, and high-risk patients need particular caution. Amylin’s gastric-emptying action and glucose effects require product-specific management rather than independent self-adjustment.